VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer

Vemurafenib, an inhibitor of mutant BRAF activity, is a promising anticancer agent for patients with BRAF-mutant metastatic melanoma. However, it is less effective in BRAF-mutant thyroid cancer, and the reason for this discrepancy is not yet fully elucidated. By RNA sequencing analysis, we identifie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Chen, Shitu, Su, Xingyun, Jiang, Xiaoxia, Zhang, Tuo, Min, Irene, Ding, Yongfeng, Wang, Xumeng, Mao, Zhuochao, Cao, Jiang, Teng, Xiaodong, Fahey, Thomas J., Wang, Weibin, Teng, Lisong
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2020
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948368/
https://ncbi.nlm.nih.gov/pubmed/31911278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados